Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

REMUS PHARMACEUTICALS LTD.

NSE : REMUSBSE : ISIN CODE : INE0O5T01011Industry : TradingHouse : Private

BSE0.000 (0 %)

PREV CLOSE ( ) NA

OPEN PRICE ( ) 0.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 0

TODAY'S LOW / HIGH ( )0.00 0.00

52 WK LOW / HIGH ( )0 0

NSE1874.0541.55 (+2.27 %)

PREV CLOSE( ) 1832.50

OPEN PRICE ( ) 1900.00

BID PRICE (QTY) 1879.35 (50)

OFFER PRICE (QTY) 1900.00 (50)

VOLUME 850

TODAY'S LOW / HIGH( ) 1872.00 1900.00

52 WK LOW / HIGH ( )1591.25 2834.75

Select year

(Rs.in Million)

Particulars

Mar 2024

Profit Before Tax

318.29

Adjustment

-7.78

Changes In working Capital

-208.83

Cash Flow after changes in Working Capital

101.68

Cash Flow from Operating Activities

36.02

Cash Flow from Investing Activities

-89.43

Cash Flow from Financing Activities

243.66

Net Cash Inflow / Outflow

190.26

Opening Cash & Cash Equivalents

78.42

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

268.68